Libido on a GLP-1: why it can go either way

Both answers are common, and that is the finding

Ask around and you will get two completely different stories. One woman feels like herself again for the first time in a decade. Another has lost interest so completely that she has started wondering what is wrong with her.

Neither of them is the exception. The evidence points in both directions at once, and I would rather show you that than pick the comfortable half.

The case that it should get better

Carrying excess weight is itself hard on sexual function — through hormones, through blood flow, and through how a woman feels in her own body. A review of the field lays out those mechanisms and how consistently the association shows up in women¹.

And when weight comes off, function tends to follow. In a randomized ancillary study within the Look AHEAD trial, 375 women with type 2 diabetes were followed for a year. Among those who had sexual dysfunction at the start, the intensive lifestyle group lost 7.6 kg against 0.45 kg in the control group — and 28% of them had remission of that dysfunction at one year, against 11% of controls². A systematic review and meta-analysis of women after bariatric surgery found improvement too³.

So the prior is genuinely optimistic: losing this much weight usually helps.

The case that it might not

Then there are the GLP-1s specifically, and here two 2026 reviews say something more uncomfortable.

The first synthesized the preclinical and clinical work on these drugs and sexual behavior. In animals, GLP-1 agonists suppressed sexual behavior in specific brain regions tied to reward and motivation. In humans the picture is mixed: reports of decreased libido do appear in the FDA's adverse event database, but the disproportionality analyses of those reports were not statistically significant⁴. That is a careful, unsatisfying answer, and it is the accurate one.

The second, written for midlife women, goes further and names the mechanism directly — that GLP-1 receptor agonists may paradoxically suppress desire and arousal through central neuroendocrine pathways, including dopamine reward signalling, even while delivering the weight loss that ought to help. Its own conclusion is that systematic clinical evidence remains limited⁵.

That mechanism is not far-fetched. These medicines act on reward and motivation circuitry; that is broadly how they quiet food noise. Desire runs through overlapping territory. It is plausible, it has not been demonstrated in women, and anyone telling you it definitely happens or definitely does not is going past the evidence.

Nothing appears on the labels either way. The Wegovy prescribing information does not mention libido at any point⁶.

Rule these out before blaming the drug

If desire has dropped, several likelier explanations deserve a look first.

• Pain or dryness. Wanting less sex when sex hurts is not a libido problem, it is a tissue problem, and low estrogen is the usual cause. It is well defined and it is treatable⁷. Sorting the physical symptoms sometimes resolves the whole question.
• Antidepressants. Sexual side effects are one of the most common reasons people stop them, and if you started or changed one in the same season as your GLP-1, the timing is doing you a disservice. That has its own page.
• Exhaustion, and being a mother. Under-eating, low iron and broken sleep flatten desire in anyone. So does the ordinary arithmetic of small children.
• Your relationship with the body you are in now. Losing a lot of weight quickly does not automatically make you comfortable being seen — sometimes the reverse, at first. That subject is not a footnote to this one.

What is worth saying out loud

If it has improved, enjoy it, and remember that returning fertility can travel with it.

If it has vanished, it is worth raising rather than absorbing. Ask for the dryness and pain to be looked at, ask about every other medicine you take, and ask about your thyroid and iron if you are also exhausted. Those are the fixable ones, and they are more likely than the drug.

And if none of them explains it, "we do not yet know what these medicines do to desire in women" is an honest place to stop — which is not the same as being told nothing is happening.